Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

PHASE3RecruitingINTERVENTIONAL
Enrollment

540

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

March 31, 2028

Study Completion Date

July 31, 2028

Conditions
Advanced Melanoma
Interventions
DRUG

Tebentafusp

Soluble gp100-specific T cell receptor with anti-CD3 scFV

DRUG

Tebentafusp with Pembrolizumab

Soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with pembrolizumab

DRUG

Investigators Choice

Investigators choice of therapy

Trial Locations (72)

1090

RECRUITING

AKH - Medizinische Universität Wien, Vienna

RECRUITING

UZ Brussel, Jette

1200

RECRUITING

Cliniques Universitaires Sain-Luc, Brussels

2065

RECRUITING

Melanoma Institute Australia, Wollstonecraft

3000

RECRUITING

UZ Leuven, Leuven

3004

RECRUITING

Alfred Health, Melbourne

4020

RECRUITING

Kepler Universitätsklinikum, Linz

4102

RECRUITING

Princess Alexandra Hospital, Woolloongabba

4120

RECRUITING

Gallipoli Medical Research Foundation (GMRF), Greenslopes

5020

RECRUITING

Universitatsklinik fur Innere Medizin 3, Salzburg

6156

RECRUITING

Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia

8036

RECRUITING

LKH - Universitaetsklinikum Graz, Graz

8058

RECRUITING

Universitaetsspital Zurich, Zurich

9000

RECRUITING

Kantonsspital St. Gallen, Sankt Gallen

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10068

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10115

RECRUITING

Charité - Campus Charité Mitte, Berlin

11042

RECRUITING

Northwell Health Cancer Institute - Zuckerberg Cancer Center, Lake Success

13005

RECRUITING

Hopital de la Timone [Recruiting], Marseille

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

19107

RECRUITING

Thomas Jefferson University Medical Oncology Clinic, Philadelphia

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20246

RECRUITING

Universitaetsklinikum Hamburg-Eppendorf, Hamburg

22075

RECRUITING

CHU de Bordeaux - Hopital Saint Andre, Bordeaux

24105

RECRUITING

Universitaetsklinikum Schleswig-Holstein, Schleswig

RECRUITING

Universitaetsklinikum Schleswig-Holstein, Kiel

28007

RECRUITING

Hospital General Universitario Gregorio Marañon, Madrid

28034

RECRUITING

Hospital Universitario Ramon y Cajal, Madrid

29010

RECRUITING

Hospital Regional Universitario de Malaga, Málaga

30322

RECRUITING

Winship Cancer Institute of Emory University, Atlanta

31059

RECRUITING

Institute Claudius Regaud, Toulouse

32224

RECRUITING

Mayo Clinic Florida, Jacksonville

32429

RECRUITING

Johannes Wesling Klinikum Minden, Minden

32806

RECRUITING

Orlando Health Cancer Institute, Orlando

37920

RECRUITING

University of Tennessee Medical Center, Knoxville

45147

RECRUITING

Universitaetsklinikum Essen, Essen

46014

RECRUITING

Hospital General Universitario de Valencia, Valencia

53100

RECRUITING

A.O.U Senese Policlinico Santa Maria alle Scotte, Siena

55905

RECRUITING

Mayo Clinic Minnesota, Rochester

60355

RECRUITING

Szpital Kliniczny im.Heliodora Swiecickiego Uniwersytetu Medycznego im.K. Marcinkowskiego w Poznaniu, Poznan

66205

RECRUITING

University of Kansas Cancer Center - Westwood, Westwood

69120

RECRUITING

Universitaetsklinikum Heidelberg, Heidelberg

69373

RECRUITING

Centre Leon Berard, Lyon

72076

RECRUITING

Universitaetsklinikum Tübingen, Tübingen

73104

RECRUITING

OU Health Stephenson Cancer Center, Oklahoma City

75010

RECRUITING

Hopital Saint Lous - APHP, Paris

77030

RECRUITING

Houston Methodist Hospital/Houston Methodist Cancer Center, Houston

80131

RECRUITING

Instituto Nazionale Tumori Fondazione G. Pascale, Napoli

80214

RECRUITING

Uniwersyteckie Centrum Kliniczne (UCK) - Klinika Onkologii i Radioterapii, Gdansk

80337

RECRUITING

LMU-Campus Innenstadt, München

84112

RECRUITING

University of Utah Huntsman Cancer Institute, Salt Lake City

85054

RECRUITING

Mayo Clinic Arizona, Phoenix

91054

RECRUITING

Universitaetsklinikum Erlangen, Erlangen

94805

RECRUITING

Institut Gustave Roussy, Villejuif

02114

RECRUITING

Massachusetts General Hospital, Boston

02215

RECRUITING

Dana Farber Cancer Institute, Boston

08901

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

M5G 2M9

RECRUITING

Princess Margaret Hospital, Toronto

01307

RECRUITING

Universitatsklinikum Carl Gustav Carus Dresden, Dresden

00168

RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

85-796

RECRUITING

Centrum Onkologii im. prof. F. Lukaszczyka w Bydgoszczy, Bydgoszcz

02781

RECRUITING

Narodowy Instytut Onkologii-im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Warsaw

08035

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

08036

RECRUITING

Hospital Clinico de Barcelona, Barcelona

CB2 0QQ

RECRUITING

Addenbrooke's Hospital, Cambridge

B15 2TH

RECRUITING

Queen Elizabeth Hospital, Birmingham

LS1 3EX

RECRUITING

Leeds General Infirmary, Leeds

SE1 9RT

RECRUITING

Guys & St Thomas' NHS Foundation Trust, London

RECRUITING

Sarah Cannon Research Institute UK, London

SW3 6JJ

RECRUITING

Royal Marsden Hospital - Chelsea, London

HA6 2RN

RECRUITING

Mount Vernon Cancer Center, Middlesex

SM2 5PT

RECRUITING

Royal Marsden Hospital - Sutton, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Immunocore Ltd

INDUSTRY

NCT05549297 - Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | Biotech Hunter | Biotech Hunter